E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
On the current trajectory, blood cancer therapies are expected to add 18.9 million life-years from 2026 to 2040.
imphoenix82
Johnson & Johnson said the CHMP opinion is an important step towards positioning the off-the-shelf immunotherapy combination of teclistamab and daratumumab as a potential new standard of care earlier in the multiple myeloma treatment pathway.
imphoenix82
The launch of the Centre of Excellence for Myeloma and Lymphoma is described as a major milestone in India’s haematology landscape.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
